SMT202000164T1 - Antagonisti del recettore cannabinoide cb1 per uso nel trattamento di malattie associate con anomalie dendritiche neuronali - Google Patents
Antagonisti del recettore cannabinoide cb1 per uso nel trattamento di malattie associate con anomalie dendritiche neuronaliInfo
- Publication number
- SMT202000164T1 SMT202000164T1 SM20200164T SMT202000164T SMT202000164T1 SM T202000164 T1 SMT202000164 T1 SM T202000164T1 SM 20200164 T SM20200164 T SM 20200164T SM T202000164 T SMT202000164 T SM T202000164T SM T202000164 T1 SMT202000164 T1 SM T202000164T1
- Authority
- SM
- San Marino
- Prior art keywords
- cannabionoid
- antagonists
- receptor
- treatment
- diseases associated
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2013/055728 WO2014146699A1 (en) | 2013-03-19 | 2013-03-19 | Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities |
| EP13710850.2A EP2976074B1 (en) | 2013-03-19 | 2013-03-19 | Antagonists of the cannabionoid receptor cb1 for use in the treatment of diseases associated with neuronal dendritic abnormalities |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SMT202000164T1 true SMT202000164T1 (it) | 2020-05-08 |
Family
ID=47901995
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SM20200164T SMT202000164T1 (it) | 2013-03-19 | 2013-03-19 | Antagonisti del recettore cannabinoide cb1 per uso nel trattamento di malattie associate con anomalie dendritiche neuronali |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9662320B2 (it) |
| EP (1) | EP2976074B1 (it) |
| CY (1) | CY1122879T1 (it) |
| DK (1) | DK2976074T3 (it) |
| ES (1) | ES2781756T3 (it) |
| HR (1) | HRP20200324T1 (it) |
| HU (1) | HUE048755T2 (it) |
| LT (1) | LT2976074T (it) |
| PL (1) | PL2976074T3 (it) |
| PT (1) | PT2976074T (it) |
| RS (1) | RS60295B1 (it) |
| SI (1) | SI2976074T1 (it) |
| SM (1) | SMT202000164T1 (it) |
| WO (1) | WO2014146699A1 (it) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2487712B (en) | 2011-01-04 | 2015-10-28 | Otsuka Pharma Co Ltd | Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy |
| GB2495118B (en) | 2011-09-29 | 2016-05-18 | Otsuka Pharma Co Ltd | A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD) |
| GB2530001B (en) | 2014-06-17 | 2019-01-16 | Gw Pharma Ltd | Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy |
| GB2531278A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiol in the treatment of intractable epilepsy |
| GB2531282A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2539472A (en) | 2015-06-17 | 2016-12-21 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2548873B (en) | 2016-03-31 | 2020-12-02 | Gw Res Ltd | Use of Cannabidiol in the Treatment of SturgeWeber Syndrome |
| GB2549278B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Use of cannabidivarin in the treatment of autism spectrum disorder |
| GB2549277B (en) | 2016-04-11 | 2021-02-17 | Gw Res Ltd | Cannabidiolic Acid for use in the Treatment of Autism Spectrum Disorder |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| GB2551986A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Parenteral formulations |
| GB2553139A (en) | 2016-08-25 | 2018-02-28 | Gw Res Ltd | Use of cannabinoids in the treatment of multiple myeloma |
| GB2557921A (en) | 2016-12-16 | 2018-07-04 | Gw Res Ltd | Use of cannabinoids in the treatment of angelman syndrome |
| GB2559774B (en) | 2017-02-17 | 2021-09-29 | Gw Res Ltd | Oral cannabinoid formulations |
| EA202090180A1 (ru) * | 2017-06-30 | 2020-05-26 | Чейс Терапьютикс Корпорейшн | Композиции nk1-антагониста и способы лечения депрессии |
| GB2568929A (en) | 2017-12-01 | 2019-06-05 | Gw Res Ltd | Use of cannabinoids in the treatment of epilepsy |
| GB2569961B (en) | 2018-01-03 | 2021-12-22 | Gw Res Ltd | Pharmaceutical |
| EP3669876A1 (en) * | 2018-12-18 | 2020-06-24 | Aelis Farma | 3béta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-one for use in the treatment of cognitive disorders |
| US11160757B1 (en) | 2020-10-12 | 2021-11-02 | GW Research Limited | pH dependent release coated microparticle cannabinoid formulations |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080255093A1 (en) * | 1999-06-14 | 2008-10-16 | Tam Peter Y | Compositions and methods for treating obesity and related disorders |
| EP1606019A1 (en) | 2003-03-07 | 2005-12-21 | The University Court of The University of Aberdeen | Cannabinoid receptor inverse agonists and neutral antagonists as therapeutic agents for the treatment of bone disorders |
| WO2005091987A2 (en) * | 2004-03-19 | 2005-10-06 | Axonyx, Inc. | Method of treating down syndrome |
| US8222293B2 (en) * | 2004-05-24 | 2012-07-17 | Regents of the University of Carolina | Treating learning deficits with inhibitors of Hmg CoA reductase |
| WO2006012403A1 (en) * | 2004-07-20 | 2006-02-02 | Massachusetts Institute Of Technology | Methods of treatment: cell signaling and glutamate release |
| WO2006124506A2 (en) * | 2005-05-13 | 2006-11-23 | Abbott Laboratories | Combination and use of drugs |
| CA2637255C (en) * | 2006-02-02 | 2018-06-12 | Novartis Ag | 40-o-(2-hydroxyethyl)-rapamycin for treating tuberous sclerosis disorders |
| US20080004313A1 (en) * | 2006-06-28 | 2008-01-03 | Mai De Ltd. | Preparation of crystalline polymorphs of rimonabant hydrochloride |
| US8003672B2 (en) * | 2008-04-21 | 2011-08-23 | Merck Sharp & Dohme Corp. | CB-1 receptor modulator formulations |
| WO2010020585A1 (en) * | 2008-08-18 | 2010-02-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Serotonin reuptake inhibitors for the treatment of rett syndrome |
| EP2544688B1 (en) * | 2010-03-02 | 2016-09-07 | President and Fellows of Harvard College | Methods and compositions for treatment of angelman syndrome |
-
2013
- 2013-03-19 SM SM20200164T patent/SMT202000164T1/it unknown
- 2013-03-19 DK DK13710850.2T patent/DK2976074T3/da active
- 2013-03-19 LT LTEP13710850.2T patent/LT2976074T/lt unknown
- 2013-03-19 RS RS20200303A patent/RS60295B1/sr unknown
- 2013-03-19 EP EP13710850.2A patent/EP2976074B1/en active Active
- 2013-03-19 US US14/778,266 patent/US9662320B2/en active Active
- 2013-03-19 SI SI201331699T patent/SI2976074T1/sl unknown
- 2013-03-19 HU HUE13710850A patent/HUE048755T2/hu unknown
- 2013-03-19 HR HRP20200324TT patent/HRP20200324T1/hr unknown
- 2013-03-19 PT PT137108502T patent/PT2976074T/pt unknown
- 2013-03-19 PL PL13710850T patent/PL2976074T3/pl unknown
- 2013-03-19 ES ES13710850T patent/ES2781756T3/es active Active
- 2013-03-19 WO PCT/EP2013/055728 patent/WO2014146699A1/en not_active Ceased
-
2020
- 2020-03-19 CY CY20201100258T patent/CY1122879T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2976074A1 (en) | 2016-01-27 |
| HUE048755T2 (hu) | 2020-08-28 |
| US20160067235A1 (en) | 2016-03-10 |
| SI2976074T1 (sl) | 2020-07-31 |
| LT2976074T (lt) | 2020-03-25 |
| CY1122879T1 (el) | 2021-05-05 |
| DK2976074T3 (da) | 2020-03-30 |
| WO2014146699A1 (en) | 2014-09-25 |
| PT2976074T (pt) | 2020-03-11 |
| RS60295B1 (sr) | 2020-07-31 |
| EP2976074B1 (en) | 2020-01-01 |
| ES2781756T3 (es) | 2020-09-07 |
| HRP20200324T1 (hr) | 2020-06-12 |
| US9662320B2 (en) | 2017-05-30 |
| PL2976074T3 (pl) | 2020-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT2976074T (pt) | Antagonistas do receptor canabinóide cb1 para utilização no tratamento de doenças associadas a anomalias dendríticas neuronais | |
| SG11201509012QA (en) | Sobetirome in the treatment of myelination diseases | |
| PL2968218T3 (pl) | Skojarzenie do leczenia choroby parkinsona | |
| PL3811943T3 (pl) | Związek do stosowania w leczeniu zaburzeń oczu | |
| HRP20190356T1 (hr) | Mimetici kalcitonina za liječenje bolesti i poremećaja | |
| SI2945642T1 (sl) | Protein faktorja 1 za uporabo pri zdravljenju ali preprečevanju bolezni | |
| PL3277280T3 (pl) | Izomiosmina do zastosowania w leczeniu chorób autoimmunologicznych | |
| EP2900266A4 (en) | TOLL-LIKE RECEPTOR-3 ANTAGONISTS FOR THE TREATMENT OF METABOLISM AND CARDIAC DISEASES | |
| HUS2000020I1 (hu) | Ciklezonid a légúti betegségek kezelésére lovaknál | |
| EP2983648A4 (en) | COMBINATION THERAPEUTIC NANOPARTICLES | |
| SI3157522T1 (sl) | Muskarinski antagonisti in njihove kombinacije za zdravljenje bolezni dihalne poti pri konjih | |
| EP3177304A4 (en) | Therapeutic nanoparticles for accumulation in the brain | |
| LT2774991T (lt) | Vaisto įvedimo sistema, skirta naudoti neurologinių sutrikimų gydymui arba diagnostikai | |
| SG11201406093VA (en) | An h3 receptor antagonist for use in the treatment of alzheimer's disease | |
| PL2956136T3 (pl) | D-fagomina do zapobiegania wystąpienia chorób autoimmunologicznych | |
| EP2958570A4 (en) | THERAPEUTIC COMPOSITION FOR THE TREATMENT OF PERIANAL DISORDERS | |
| GB201320112D0 (en) | Calcitonin Mimetics for treating diseases and disorders | |
| GB201306413D0 (en) | The local treatment of ophthalmic diseases |